ONCY

0.350110.37%
JK

Jared Kelly

CEO & Director

Mr. Jared Kelly, J.D., L.L.M, was Senior VP, General Counsel & Corporate Secretary of Ambrx Biopharma Inc. from June 2023 until 2024. Mr. Kelly has extensive experience of advising public companies on corporate governance, financing transactions and mergers and acquisitions to Ambrx. He is CEO & Director of Oncolytics Biotech Inc. from June 11, 2025. Mr. Kelly is an experienced public company lawyer who began his career with Kirkland & Ellis LLP where he represented various public companies in securities offerings, IPOs and merger transactions. He played a central role in orchestrating the sale of Ambrx Biopharma to Johnson & Johnson for 2 billion. He served as a Partner at Lowenstein Sandler LLP where his practice focused on representing biotechnology companies in financing transactions, mergers and acquisitions and other complex transactions. Mr. Kelly received his J. D. and an LL. M. in Securities and Financial Regulation from Georgetown University Law Center, where he was the recipient of multiple honors and fellowships, including the Lane Evans Fellowship and Decrane Scholarship.

Positions